Individualized Temporally Interfering Electrical Stimulation in Major Depressive Disorder
NCT07924917, Not applicable, Recruiting, Tianjin Medical University General Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Individualized Temporally Interfering Electrical Stimulation in Major Depressive Disorder | ClinicalTrials.gov |
| NCT number | NCT07924917 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 75 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Tianjin Medical University General Hospital | ClinicalTrials.gov |
| Conditions | Major Depressive Disorder (MDD) | ClinicalTrials.gov |
| Interventions | Single-target active temporally interfering electrical stimulation, Dual-target active temporally interfering electrical stimulation, Sham temporally interfering electrical stimulation | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Hamilton Depression Rating Scale 17-item (HAMD-17) | Baseline, Week 1, Week 2, Week 4. | Total scores range from 0 to 52, with higher scores indicating greater depressive symptom severity (worse outcomes). | ClinicalTrials.gov |
| Secondary | Patient Health Questionnaire-9 (PHQ-9) | Baseline, Week 1, Week 2, Week 4. | Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity (worse outcomes). | ClinicalTrials.gov |
| Secondary | Hamilton Anxiety Rating Scale (HAMA) | Baseline, Week 1, Week 2, Week 4. | Total scores range from 0 to 56, with higher scores indicating greater anxiety symptom severity (worse outcomes). | ClinicalTrials.gov |
| Secondary | Generalized Anxiety Disorder 7-item (GAD-7) | Baseline, Week 1, Week 2, Week 4. | Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity (worse outcomes). | ClinicalTrials.gov |
| Secondary | Young Mania Rating Scale (YMRS) | Baseline, Week 1, Week 2, Week 4. | Total scores range from 0 to 60, with higher scores indicating greater manic symptom severity (worse outcomes). | ClinicalTrials.gov |
| Secondary | Electroencephalographic (EEG) Power in the Gamma Frequency Band | Baseline, Week 1, Week 2, Week 4. | Gamma-band EEG power will be assessed using spectral analysis of EEG recordings. | ClinicalTrials.gov |
| Secondary | 40-Hz Auditory Steady-State Response (ASSR) Event-Related Spectral Perturbation (ERSP) | Baseline, Week 1, Week 2, Week 4. | The 40-Hz ASSR will be assessed using electroencephalography (EEG). Event-related spectral perturbation (ERSP) quantifies stimulus-induced changes in oscillatory power relative to a prestimulus baseline. ERSP will be expressed in decibels (dB), with higher values indicating greater stimulus-related power enhancement. | ClinicalTrials.gov |
| Secondary | 40-Hz Auditory Steady-State Response (ASSR) Inter-Trial Coherence (ITC) | Baseline, Week 1, Week 2, Week 4. | The 40-Hz ASSR will be assessed using electroencephalography (EEG). Inter-trial coherence (ITC) quantifies the consistency of oscillatory phase across repeated auditory stimulus presentations. ITC values range from 0 to 1, with higher values indicating greater phase consistency. | ClinicalTrials.gov |
| Secondary | Magnetic Resonance Imaging (MRI) | Baseline, Week 2. | Changes in brain structure and functional organization, assessed using MRI, will be included as secondary neuroimaging outcomes. | ClinicalTrials.gov |
| Other | Athens Insomnia Scale (AIS) | Baseline, Week 1, Week 2, Week 4. | Total scores range from 0 to 24, with higher scores indicating greater insomnia symptom severity (worse outcomes). | ClinicalTrials.gov |
| Other | Attention Control Scale (ACS) | Baseline, Week 1, Week 2, Week 4. | The ACS consists of 20 items assessing two dimensions of attentional control: Attentional Focusing and Attentional Shifting. Total scores range from 20 to 80, with higher scores indicating better overall attentional control abilities (better outcomes). Attentional Focusing reflects the ability to maintain attention and resist distractions, whereas Attentional Shifting reflects the ability to flexibly shift attention between tasks or stimuli. | ClinicalTrials.gov |
| Other | Chinese 10-item Rumination Response Scale (RRS-10) | Baseline, Week 1, Week 2, Week 4. | The RRS-10 consists of 10 items assessing two dimensions of rumination: Brooding and Reflection, each comprising five items. Total scores range from 10 to 40, with higher scores indicating greater overall rumination (generally worse outcomes). Brooding reflects maladaptive rumination, whereas Reflection reflects purposeful self-focused thinking and does not necessarily indicate worse outcomes. | ClinicalTrials.gov |
| Other | Emotion Regulation Questionnaire (ERQ) - Cognitive Reappraisal Subscale | Baseline, Week 1, Week 2, Week 4. | The Cognitive Reappraisal subscale of the ERQ consists of 6 items assessing the tendency to regulate emotions by reinterpreting emotional situations. Total scores range from 6 to 42, with higher scores indicating greater use of cognitive reappraisal, generally considered a more adaptive emotion regulation strategy (better outcomes). | ClinicalTrials.gov |
| Other | Emotion Regulation Questionnaire (ERQ) - Expressive Suppression Subscale | Baseline, Week 1, Week 2, Week 4. | The Expressive Suppression subscale of the ERQ consists of 4 items assessing the tendency to inhibit outward emotional expression. Total scores range from 4 to 28, with higher scores indicating greater use of expressive suppression, generally considered a less adaptive emotion regulation strategy (worse outcomes). | ClinicalTrials.gov |
| Other | Cognitive Flexibility Inventory (CFI) | Baseline, Week 1, Week 2, Week 4. | The CFI consists of 20 items assessing two dimensions of cognitive flexibility: Alternatives (13 items) and Control (7 items). Total scores range from 20 to 100, with higher scores indicating greater cognitive flexibility (better outcomes). Alternatives reflects the ability to generate multiple explanations and solutions to difficult situations, whereas Control reflects the tendency to perceive difficult situations as controllable. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)